Cancer immunotherapy may increase risk of developing rheumatologic disorders
The goal of harnessing the immune system to fight cancer is not new; it dates back 125 years to when William Coley advocated that the body’s response to…
m.ard.bmj.com
Although the checkpoint inhibitors are called targeted therapies, they are not specific. They bind specifically to the cellular receptors they are designed to bind, but they non-specifically up-regulate all activated T-cells regardless of their recognised targets.
So, all’s good if most of the strongly activated T-cells recognise and hunt down the tumour cells or infected cells; not good (disastrous even) if T-cells sensitised to self-antigens go on the rampage. Autoimmunity is the result.
So, all’s good if most of the strongly activated T-cells recognise and hunt down the tumour cells or infected cells; not good (disastrous even) if T-cells sensitised to self-antigens go on the rampage. Autoimmunity is the result.
Arthritis Emerges After Cancer Immunotherapy
In cancer treatment, a novel type of adverse effect
medpagetoday.com
Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities
Immune checkpoint inhibitors (ICIs) are newly approved treatments for advanced malignancies that are increasing survival. The mechanism of these drugs,…
rmdopenbeta.bmj.com
Original Article from The New England Journal of Medicine — Fulminant Myocarditis with Combination…
nejm.org
Combination checkpoint inhibitors work better against cancer, but the autoimmune side-effects are worse.
Immune System, Unleashed by Cancer Therapies, Can Attack Organs
nytimes.com|By Matt Richtel